The National Agency for Food and Drug Administration and Control (NAFDAC) has issued a public alert regarding the circulation of counterfeit Artemether/Lumefantrine tablets in Nigeria, falsely branded as Aflotin 20/120. In a post shared on its official X handle on Tuesday, NAFDAC revealed that the fake medication was identified and reported by Ajanta Pharma Limited, the legitimate manufacturer based in Mumbai, India. The company disclosed that it originally produced batch number PA2128L in December 2018 as Combisunate 20/120 (Artemether 20mg/Lumefantrine 120mg), with an expiry date of November 2020, packaged in 30 x 24 tablet packs. However, the batch has been counterfeited and repackaged as Aflotin 20/120mg in 1 x 18 tablet packs. NAFDAC noted that the overprinted labeling on the counterfeit product did not align with Ajanta Pharma’s authentic style. Following an investigation and inspection of the product, Ajanta Pharma confirmed that the Aflotin 20/120mg with Batch No: PA2128L currently found in Nigeria is a fake. “The genuine Aflotin 20/120 tablet is a combination of Artemether/Lumefantrine (20mg/120mg) and is primarily used for the treatment of uncomplicated malaria caused by the Plasmodium falciparum parasite,” it said. The regulatory agency emphasised that counterfeit medicines endanger people’s health because they do not comply with regulatory standards, which means the safety, quality, and efficacy of these products are not ensured. “The use of counterfeit medicines often fail to treat diseases or conditions effectively, leading to serious health consequences, including death,” NAFDAC said. It said all NAFDAC zonal directors and state coordinators had been informed and directed to conduct surveillance and remove any counterfeit products found within their zones and states. NAFDAC further urged distributors, retailers, healthcare professionals, and caregivers to remain cautious and vigilant throughout the supply chain to prevent the distribution, sale, or use of counterfeit medicines. The agency emphasized that all medical products should be sourced exclusively from authorised or licensed suppliers.